Neema Wagley, Author at MPM BioImpact

Skip to content

About
Team
Portfolio
News
Contact
Investor Login

29th January 2025

Cullinan Therapeutics Announces Primary Endpoint Met in Phase 2b Trial of Zipalertinib

Building Companies to

Transform
patient outcomes.

Connect with us

LinkedIn Twitter

Contact

info@mpmcapital.com

399 Boylston Street, Suite 1100
Boston, MA 02116
617-425-9200

map

© 2025

MPM BioImpact LLC. All Rights Reserved. Terms of Use | Privacy Policy

BIOIMPACT, MPM, MPM CAPITAL, BIOIMPACT EQUITIES, OIF, ONCOLOGY IMPACT FUND are registered trademarks, and BIOIMPACT logo, MPM BIOIMPACT logo, OIF2 logo, BIOIMPACT CAPITAL MANAGEMENT, BIOIMPACT EQUITIES, BIOIMPACT FUND, MEDICAL IMPACT MANAGEMENT, MIM are trademarks of MPM BioImpact LLC, BioImpact Capital LLC, MPM Capital LLC, and MPM Capital LP.

Top

You are about to leave MPM BioImpact's website. MPM BioImpact is not responsible for the content on other companies' websites.

Cancel Continue